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Everolimus allows calcineurin-inhibitor reduction
without loss of efficacy and may improve renal-
transplant outcomes. In a 24-month, open-label study,
833 de novo renal-transplant recipients were random-
ized to everolimus 1.5 or 3.0 mg/day (target troughs
3–8 and 6–12 ng/mL, respectively) with reduced-
exposure CsA, or mycophenolic acid (MPA) 1.44 g/day
plus standard-exposure CsA. Patients received basil-
iximab ± corticosteroids. The primary endpoint was
composite efficacy failure (treated biopsy-proven acute
rejection, graft loss, death or loss to follow-up)
and the main safety endpoint was renal function
(estimated glomerular filtration rate [eGFR], by Modi-
fication of Diet in Renal Disease [MDRD]) at Month 12
(last-observation-carried-forward analyses). Month 12
efficacy failure rates were noninferior in the everolimus
1.5 mg (25.3%) and 3.0 mg (21.9%) versus MPA (24.2%)
groups. Mean eGFR at Month 12 was noninferior in
the everolimus groups versus the MPA group (54.6 and
51.3 vs 52.2 mL/min/1.73 m2 in the everolimus 1.5 mg,
3.0 mg and MPA groups, respectively; 95% confidence
intervals for everolimus 1.5 mg and 3.0 mg vs MPA:
−1.7, 6.4 and −5.0, 3.2, respectively). The overall in-
cidence of adverse events was comparable between
groups. The use of everolimus with progressive reduc-
tion in CsA exposure, up to 60% at 1 year, resulted
in similar efficacy and renal function compared with
standard-exposure CsA plus MPA.
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Introduction
Although advances in immunosuppressive therapy have
dramatically improved short-term outcomes following renal
transplantation, long-term graft survival has not improved
to the same extent. The nephrotoxicity of calcineurin
inhibitors (CNIs) contributes to chronic graft dysfunction
(1), and since renal function at 12 months posttransplant
potentially predicts long-term graft function (2–4), optimiz-
ing renal function is critical. Thus, a key challenge is to de-
velop immunosuppressive strategies that allow early CNI
minimization or elimination and lead to the reduction of
CNI-related adverse events (AEs) while maintaining cur-
rent low acute-rejection rates.
Everolimus is a mammalian target of rapamycin (mTOR)
inhibitor/proliferation-signal inhibitor (PSI) with potent
immunosuppressive and antiproliferative effects (5), and
is highly effective in preventing acute rejection in renal-
transplant recipients (6–9). Although, in initial trials,
everolimus plus standard-exposure CsA (ST-CsA) demon-
strated equivalent efficacy to MMF plus ST-CsA in de novo
renal-transplant recipients, renal function was reduced in
everolimus-treated patients (6,9,10). However, Phase III
studies have demonstrated that everolimus allows early
CNI minimization while maintaining good efficacy and
renal function (7). Various everolimus and CsA dosing
regimens have been assessed (11–14), culminating in a
regimen that minimizes the risk of rejection by targeting
specific everolimus trough levels, while reducing the risk
of CNI nephrotoxicity by CNI minimization.
The A2309 study assessed the efficacy and safety of two
regimens of everolimus plus reduced-exposure CsA (RD-
CsA) compared with mycophenolic acid (MPA) plus ST-CsA
in de novo renal-transplant recipients over 24 months. This
report details the 12-month results.
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Materials and Methods
Study design
This study was a Phase IIIb, 24-month, multicenter, open-label trial. Eligible
patients were randomized (1:1:1) to one of three treatment groups within
24 hours posttransplantation:
• Everolimus 1.5 mg (0.75 mg p.o. b.i.d. targeted to 3–8 ng/mL) +
RD-CsA.
• Everolimus 3.0 mg (1.50 mg p.o. b.i.d. targeted to 6–12 ng/mL) +
RD-CsA.
• MPA 1.44 g (720 mg p.o. b.i.d.) + ST-CsA.
All patients received basiliximab induction therapy ± corticosteroids. Pa-
tients were assigned a randomization number, which was linked to one of
the three treatment groups, using an interactive voice-response system.
The randomization scheme was reviewed and approved by the Biostatis-
tics Quality Assurance Group. The institutional review board of each center
approved the study protocol, and all patients provided written informed
consent.
Patients
Patients aged 18–70 years undergoing primary kidney transplantation were
eligible. Key exclusion criteria included, kidneys donated after cardiac death
or with a cold ischemia time >40 hours; donor age >65 years; recipi-
ents of multiorgan-, ABO-incompatible-, positive T-cell cross-match- or HLA-
identical living-related-donor transplants; or most recent anti-HLA Class I
panel-reactive antibodies (PRA) >20% by a CDC (complement-dependent
cytotoxicity)-based assay or >50% by flow cytometry or ELISA.
Immunosuppressive therapy
Eligible patients received basiliximab (20 mg) within the 2 hours prior to
transplantation and 20 mg at Day 4, or according to local practice. Patients
received their first dose of study drug within 24 hours posttransplantation.
From Day 5, CsA dose adjustments were made based on trough levels
(Supporting Table 1). Everolimus doses were adjusted from Day 5 onward:
• Everolimus 1.5 mg group: targeted to 3–8 ng/mL.
• Everolimus 3.0 mg group: targeted to 6–12 ng/mL.
Trough levels were assessed at a central laboratory using liquid
chromatography-mass spectrometry. Blood samples were taken 3–7 days
following each visit in which patients’ everolimus or CsA doses were
changed. Corticosteroids were administered according to local practice.
Dose reductions were permitted for patients experiencing decreases in
white blood cell (WBC) or platelet counts, increases in cholesterol or triglyc-
eride levels, or other AEs, to keep patients on the study drug. Study
drug interruptions were permitted during antibody treatment of rejection
episodes.
CMV prophylaxis (≥30 days; ganciclovir, CMV hyperimmune globulin,
acyclovir or valacyclovir; according to local practice) was mandatory for
all CMV-negative recipients who received a kidney from a CMV-positive
donor. Other patients received CMV prophylaxis according to local prac-
tice. Pneumocystis carinii pneumonia prophylaxis was initiated when
oral medication was tolerated and continued for the first year of the
study.
Efficacy and safety
Efficacy: The primary endpoint was efficacy failure, defined as the com-
posite of treated biopsy-proven acute rejection (BPAR), graft loss, death or
loss to follow-up at Month 12. The main secondary endpoint was the com-
posite of graft loss, death or loss to follow-up at Month 12. In suspected
rejection episodes, regardless of antirejection treatment, an allograft-core
biopsy was performed within 48 hours. Biopsies were read by local patholo-
gists according to 1997 updated Banff criteria (15) and by a central patholo-
gist, blinded to the patient’s treatment. The primary endpoint was assessed
using the local pathologists’ readings. Other secondary endpoints included
the components of the primary endpoint.
Safety: The main safety endpoint was renal function at Month 12,
assessed by estimated glomerular filtration rate (eGFR) calculated using the
Modification of Diet in Renal Disease (MDRD) formula (16). Renal function
was also assessed by using the Nankivell formula (17) to calculate eGFR,
the Cockcroft–Gault formula to estimate creatinine clearance and by mea-
suring serum creatinine. Other safety assessments included AEs, serious
AEs (SAEs), clinical laboratory measurements (biochemistry, hematology
and urinalysis) and vital signs.
Statistical analyses
The primary efficacy analyses were conducted on the intent-to-treat (ITT)
population (all patients randomized). Noninferiority was assessed using a
two-sided 0.025-level z-test analyzed by the modified Bonferroni testing
procedure (18) to control for multiple comparisons and maintain the overall
Type I error rate at a = 0.05. Everolimus was considered noninferior to MPA
if the upper limit of the 95% confidence interval (CI) was less than 10%.
Additional supportive analyses of the primary efficacy endpoint included
repeating the z-test using the per-protocol population (ITT minus patients
with major protocol deviations), performing a Kaplan–Meier (K–M) survival
analysis and analyzing BPAR based on central pathologist readings. A K–
M analysis of BPAR was used to estimate the probability of experiencing
an event and to compare the time to event between treatment groups.
The method used for the primary efficacy analyses was also used for the
main secondary efficacy endpoints. For the main safety endpoint, renal
function was compared using t-test-based 95% CI for the difference in
mean eGFR at Month 12 between everolimus and MPA (ITT population).
A last-observation-carried-forward (LOCF) approach was used to impute
missing eGFR values for the 12-month analyses, with a value of zero en-
tered for patients with graft loss. Everolimus was considered noninferior
to MPA if the lower limit of the 95% CI was greater than −8 mL/min/
1.73 m2. Summary statistics were provided for calculated eGFRs and dif-
ferences between everolimus and MPA responses were compared by the
Wilcoxon Rank–Sum test. Renal function was also assessed using data ob-
served while patients remained on treatment (no later than 2 days after the
discontinuation of study medication). Except for the renal-function analy-
ses, safety analyses were performed on the safety population (patients
who received at least one dose of study drug and had a postbaseline safety
assessment).
Sample size calculation
The efficacy failure rates at Month 12 for the everolimus and MPA groups
were assumed to be 19% and 20%, respectively. A sample size of 825
patients (275 per group) was calculated to have an 84% power to demon-
strate that everolimus was not more than 10% inferior to MPA with respect
to the primary endpoint.
For the mean eGFR (MDRD) noninferiority assessment, the sample-size
calculation was based on the 95% CI of a two-sided t-test. A significance
level of 0.025 was used to control for multiple comparisons. It was assumed
that the MPA and everolimus groups would have a 12-month mean eGFR
of 50 mL/min/1.73 m2 and a SD of 22 mL/min/1.73 m2. Based on these
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assumptions, a sample size of 825 patients (275 per group) would have
97% power to demonstrate that mean eGFR in the everolimus groups was
noninferior to the MPA group by ≥8 mL/min/1.73 m2.
Results
Baseline demographics
In total, 833 patients were randomized to the everolimus
1.5 mg (n = 277), 3.0 mg (n = 279), or MPA (n = 277)
groups. A total of 595 (71.4%) patients remained on study
medication at Month 12; AEs were the most frequent rea-
son for study-drug discontinuation in all groups (Figure 1).
Donor and recipient characteristics were generally compa-
rable between groups (Table 1).
Immunosuppressive therapy
Mean everolimus trough levels were within the target
ranges at all time points (Figure 2). From Month 1 onward
76–85% of patients in the 1.5 mg group were within the
target range versus 60–69% in the 3.0 mg group (Support-
ing Table 2).
Per protocol, CsA doses were reduced over time. In the
everolimus groups, >50% of patients had CsA trough lev-
els within the target range from Day 14 onward, with the
exception of Months 4, 6 and 7. In the MPA group, >50%
of patients had trough levels within the target range from
Month 1 onward (Figure 3; Supporting Table 2). Compared
with the MPA group, the percentage reductions in mean
CsA trough levels at Months 1, 6 and 12 were 31%, 46%
and 60%, respectively, for the everolimus 1.5 mg and 29%,
51% and 64%, respectively, for the 3.0 mg groups. Mean
MPA doses in the control group were constant through-
out the study; the overall mean dose (SD) of MPA was
1.34 g/day (0.210).
Efficacy
Primary efficacy endpoint: Composite efficacy failure
event rates at Month 12 were 25.3%, 21.9% and 24.2%
in the everolimus 1.5 mg, 3.0 mg and MPA groups, respec-
tively; both everolimus groups were statistically noninferior
to MPA (Table 2). No statistical differences were observed
between the groups in terms of the K–M estimate of the
proportion of patients free from composite efficacy failure
at Month 12 (74.7%, 78.1% and 75.8% in the everolimus
1.5 mg, 3.0 mg and MPA groups, respectively; p ≥ 0.300
for all comparisons).
Per-protocol population analyses confirmed the primary ITT
analyses findings, with similar composite efficacy failure
rates reported for the everolimus 1.5 mg (15.8%), 3.0 mg
(12.2%) and MPA groups (15.7%). Similar results were
reported when the incidence of treated BPAR was based
on central laboratory biopsy analyses (data not shown).
Secondary efficacy endpoints: The combined incidence
of death, graft loss and loss to follow-up at Month 12
was 11.6%, 11.1% and 9.4% in the everolimus 1.5 mg,
3.0 mg and MPA groups, respectively (statistically nonin-
ferior for everolimus vs MPA) (Table 2). In total, 53, 42
and 54 treated BPARs were reported in the everolimus
1.5 mg, 3.0 mg and MPA groups, respectively. A majority
were Banff type IA (Table 2). The K–M estimate of patients
free from treated BPAR (95% CI) at Month 12 (ITT popu-
lation) was 82.7% (78.1, 87.3) in the everolimus 1.5 mg,
86.0% (81.9, 90.2) in the 3.0 mg and 82.4% (77.8, 87.0) in
the MPA groups (Figure 4). Rates of antibody-treated rejec-
tion were similar between groups: 3.6%, 4.3% and 5.4%,
respectively (statistically noninferior for the everolimus vs
MPA groups). Differences in the incidence of graft loss
were not significant between the groups with 4.3% of
patients in the everolimus 1.5 mg, 4.7% in the 3.0 mg
and 3.2% in the MPA groups experiencing graft loss by
Month 12 (p = 0.504 and p = 0.393 vs MPA, respectively)
(Table 2).
Safety
Renal function: For the main safety endpoint analyses
at Month 12 (LOCF analyses), mean eGFR (MDRD) was
54.6, 51.3 and 52.2 mL/min/1.73 m2 in the everolimus
1.5 mg, 3.0 mg and MPA groups, respectively. Renal func-
tion in both everolimus groups was statistically noninfe-
rior to MPA, since the lower limits of the 95% CI for the
mean eGFR difference in the everolimus 1.5 mg (−1.7,
6.4) and 3.0 mg (−5.0, 3.2) versus MPA groups were
greater than −8 mL/min/1.73 m2. Mean and median calcu-
lated eGFR (MDRD) showed similar patterns of renal func-
tion over the 12-month period (on-treatment population).
Significantly higher eGFR values were reported at Months
1, 6, 7 and 9 in the everolimus 1.5 mg versus MPA groups
(Table 3, Figure 5). When renal function was assessed by
creatinine clearance (Cockcroft–Gault) and Nankivell eGFR
methods, a similar pattern was observed with the high-
est values generally in the everolimus 1.5 mg group (tar-
geted to 3–8 ng/mL) (Table 3). The National Kidney Foun-
dation (NKF) criteria for chronic kidney disease Stage 3
(eGFR 30–59 mL/min/1.73 m2) and Stage 4 (eGFR 15–
29 mL/min/1.73 m2) were used as a guide to evaluate
renal function by category. Of the patients whose re-
nal function was <60 mL/min/1.73 m2 at Month 1 (<30
and 30–<60 mL/min/1.73 m2 categories), a total of 20%
(25/127) of patients in the everolimus 1.5 mg group ex-
perienced an increase in GFR to ≥60 mL/min/1.73 m2
by Month 12 versus only 15% (20/132) and 12%
(18/145) in the 3.0 mg and MPA groups, respectively.
The mean eGFR changes in individual categories are pre-
sented in Table 3. Delayed graft function was compara-
ble between treatment groups (10.2%, 10.4% and 9.2%
in the everolimus 1.5 mg, 3.0 mg and MPA groups,
respectively).
Adverse events: The overall incidence of AEs was com-
parable between groups: 98.9%, 99.3% and 98.9% of
patients in the everolimus 1.5 mg, 3.0 mg and MPA groups,
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Figure 1: Patient disposition. ITT population = all patients randomized after transplantation; PP population = all patients who completed
study without major protocol deviations, i.e. patients who had received multiple or previous transplants; kidneys with cold ischemia time
>40 hours; or a kidney from a donor aged >65 years; Safety population: all patients who received at least one dose of study drug and had
at least one postbaseline safety assessment; ∗primary reason for discontinuation listed; AEs = adverse events; ITT = intention-to-treat;
MPA = mycophenolic acid; PP = per protocol.
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Table 1: Baseline demographics and clinical characteristics of renal-transplant recipients and donors (intent-to-treat population)
Everolimus 1.5 mg Everolimus 3.0 mg MPA 1.44 g
(N = 277) (N = 279) (N = 277)
Recipient characteristics
Age, years ± SD 45.7 ± 12.7 45.3 ± 13.4 47.2 ± 12.7
Male, n (%) 176 (63.5) 191 (68.5) 189 (68.2)
Caucasian, n (%) 193 (69.7) 180 (64.5) 190 (68.6)
BMI, n (%)
≤25th percentile (22.2) 71 (25.6) 73 (26.2) 57 (20.6)
>25th percentile, ≤50th percentile (25.1) 64 (23.1) 57 (20.4) 70 (25.3)
>50th percentile, ≤75th percentile (29.0) 69 (24.9) 60 (21.5) 75 (27.1)
>75th percentile 61 (22.0) 74 (26.5) 62 (22.4)
Unknown 12 (4.3) 15 (5.4) 13 (4.7)
Primary disease leading to transplantation, n (%)
Hypertension/nephrosclerosis 50 (18.1) 56 (20.1) 45 (16.2)
Glomerulonephritis/glomerular disease 43 (15.5) 55 (19.7) 40 (14.4)
Diabetes mellitus 39 (14.1) 29 (10.4) 45 (16.2)
Polycystic disease 36 (13.0) 29 (10.4) 33 (11.9)
Unknown 34 (12.3) 37 (13.3) 39 (14.1)
Other1 74 (26.7) 73 (26.2) 74 (26.7)
Missing 1 (0.4) 0 (0.0) 1 (0.4)
Current dialysis, n (%)†
Hemodialysis 182 (65.7) 197 (70.6) 188 (67.9)
Peritoneal dialysis 48 (17.3) 45 (16.1) 42 (15.2)
None 46 (16.6) 37 (13.3) 46 (16.6)
Number of HLA mismatches, n (%)
0 10 (3.6) 15 (5.4) 15 (5.4)
1 19 (6.9) 18 (6.5) 19 (6.9)
2 37 (13.4) 51 (18.3) 40 (14.4)
≥3 210 (75.8) 194 (69.5) 202 (72.9)
CMV serology status, n (%)
Negative 94 (33.9) 83 (29.7) 104 (37.5)
Positive 180 (65.0) 188 (67.4) 170 (61.4)
CMV donor/recipient serology status, n (%)
Donor positive/recipient positive 140 (50.5) 139 (49.8) 125 (45.1)
Donor positive/recipient negative 30 (10.8) 28 (10.0) 42 (15.2)
Donor negative/recipient positive 36 (13.0) 44 (15.8) 39 (14.1)
Donor negative/recipient negative 62 (22.4) 53 (19.0) 60 (21.7)
Missing 9 (3.2) 15 (5.4) 11 (4.0)
Donor characteristics
Age, years ± SD 41.4 ± 13.9 41.1 ± 13.0 41.8 ± 13.6
Male, n (%) 154 (55.6) 139 (49.8) 136 (49.1)
Caucasian, n (%) 193 (69.7) 191 (68.5) 197 (71.1)
Deceased donor heart beating, n (%) 128 (46.2) 126 (45.2) 127 (45.8)
Donated after cardiac death, n (%) 1 (0.4) 2 (0.7) 1 (0.4)
Living related, n (%) 99 (35.7) 111 (39.8) 101 (36.5)
Living unrelated, n (%) 48 (17.3) 40 (14.3) 47 (17.0)
Missing, n (%) 1 (0.4) 0 (0.0) 1 (0.4)
1Includes pyelonephritis, drug-induced toxicity, interstitial nephritis, vasculitis, obstructive disorder/reflux, renal hyperplasia/dysplasia, IgA
nephropathy and other causes; †Data not available for one patient in the everolimus 1.5 mg and MPA groups.
ITT = intent-to-treat; MPA = mycophenolic acid; SD = standard deviation.
respectively. SAEs were also comparable (56.6%, 60.4%
and 53.8%, respectively) (Table 4). The incidence of AEs
by system organ class was generally similar between
groups and a majority were mild-to-moderate in severity.
Neoplasms were infrequent in all groups (3.3%, 2.9% and
5.9% of patients in the everolimus 1.5 mg, 3.0 mg and
MPA groups, respectively) while AEs generally ascribed to
CsA or PSI/mTOR inhibitors were reported more frequently
in the MPA and everolimus groups, respectively (Table 4).
Posttransplant diabetes mellitus, as assessed by the in-
vestigator, was reported as an AE in a similar percentage
of patients in each group (5.1%, 7.9% and 7.0% in the
1.5 mg, 3.0 mg and MPA groups, respectively).
Infections and infestations were reported as AEs in 61.7%,
64.0% and 67.8% of patients in the everolimus 1.5 mg,
3.0 mg and MPA groups, respectively. The most fre-
quent was urinary tract infection (Table 4), with comparable
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Figure 2: Target range and actual mean trough levels of everolimus achieved (ng/mL) over time in the everolimus 1.5 mg and
3.0 mg groups (safety population). Everolimus target ranges were 3–8 ng/mL and 6–12 ng/mL in the 1.5 mg and 3.0 mg everolimus
groups, respectively; mean everolimus doses in mg/day (SD) at Day 1, Month 6 and Month 12 were 3.2 (22.6), 2.5 (10.1) and 2.6 (10.6)
in the 1.5 mg group and 2.7 (0.5), 2.7 (1.0) and 3.4 (9.8) in the 3.0 mg group, respectively; the maximum doses of everolimus reported in
some cases were implausibly high and these were likely to be administrative errors.
Figure 3: Target range and actual mean trough levels of CsA achieved (ng/mL) over time in the everolimus 1.5 mg, 3.0 mg and
mycophenolic acid 1.44 g groups (safety population). CsA target ranges for the everolimus groups were 100–200 ng/mL from Day 3
decreasing to 75–150 ng/mL from Month 2, 50–100 ng/mL from Month 4 and 25–50 ng/mL from Months 6 to 12; CsA target ranges for
the MPA groups were 200–300 ng/mL from Day 3 decreasing to 100–250 ng/mL from Months 2 to 12; MPA = mycophenolic acid.
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Table 2: Summary of efficacy-related results over 12 months of treatment (ITT population1)
Everolimus 1.5 mg Everolimus 3.0 mg
N = 277 N = 279
MPA 1.44 g
Event rate difference Event rate difference N = 277
n (%) (95% CI) vs control n (%) (95% CI) vs control n (%)
Primary composite endpoint2 70 (25.3) 1.1 (−6.1, 8.3) 61 (21.9) −2.7 (−9.3, 4.7) 67 (24.2)
Death 7 (2.5) 9 (3.2) 6 (2.2)
Graft loss 12 (4.3) 13 (4.7) 9 (3.2)
Loss to follow up3 12 (4.3) 8 (2.9) 9 (3.2)
Treated BPAR4 45 (16.2) 37 (13.3) 47 (17.0)
Number of treated BPAR of any grade5 53 42 54
Patients with treated BPAR by Banff grade
IA 21 (7.6) 16 (5.7) 22 (7.9)
IB 11 (4.0) 8 (2.9) 7 (2.5)
IIA 7 (2.5) 9 (3.2) 15 (5.4)
IIB 1 (0.4) 3 (1.1) 2 (0.7)
III 1 (0.4) 0 (0.0) 1 (0.4)
Missing 6 (2.2) 4 (1.4) 3 (1.1)
Death, graft loss or loss to follow up2,6,7 32 (11.6) 2.2 (−2.9, 7.3) 31 (11.1) 1.7 (−3.3, 6.8) 26 (9.4)
Death or graft loss 18 (6.5) 1.1 (−2.9, 5.0) 21 (7.5) 2.1 (−2.0, 6.2) 15 (5.4)
1Last-observation-carried-forward analyses; 2Both everolimus groups were non-inferior to the MPA group; 3Loss to follow-up patient for
primary composite endpoint is a patient who did not experience treated BPAR, graft loss or death and whose last day of contact is
prior to Day 316; 4First treated BPAR; 5Some patients experienced >1 BPAR; 6Main secondary endpoint; 7Loss to follow-up patient for
secondary endpoint is a patient who did not experience graft loss or death and whose last day of contact is prior to Day 316.
BPAR = biopsy-proven acute rejection; CI = confidence interval; ITT = intent-to-treat; MPA = mycophenolic acid.
severity between groups. A higher incidence of BK viruria
and BK viremia was observed in the MPA (3.3% and 1.8%)
versus everolimus groups (everolimus 1.5 mg: 0.7% and
1.1%; and 3.0 mg: 0.4% and 0.7%) and a further three BK
nephropathy cases were confirmed by histology: 0.4%,
0.0% and 0.7% in the everolimus 1.5 mg, 3.0 mg and
MPA groups, respectively. CMV infection was observed
in a higher proportion of patients in the MPA (5.9%) ver-
sus everolimus groups (0.7% and 0.0% in the everolimus
1.5 mg and 3.0 mg groups, respectively). Similarly, the in-
cidence of CMV syndrome and CMV disease was higher
in the MPA group (everolimus 1.5 mg: 1.5% and 0.7%;
Figure 4: Kaplan–Meier estimate of
time to biopsy-proven acute rejec-
tion over 12 months of treatment
(intent-to-treat population). Analyses
are based on local laboratory data;
MPA = mycophenolic acid.
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Figure 5: Mean calculated glomerular filtration rate (Modification of Diet in Renal Disease formula) over time by treatment group
(intent-to-treat population; on-treatment values). On-treatment values include any assessment obtained no later than 2 days after
discontinuation of study medication; mean eGFR was numerically higher (1.9 mL/min/1.73 m2) in the everolimus 1.5 mg versus the MPA
group at Month 12 with the mean increase from Months 1 to 12 ranging from 1.8–5.1 mL/min/1.73 m2; eGFR = estimated glomerular
filtration rate; ITT = intent-to-treat; MPA = mycophenolic acid.
3.0 mg: 1.4% and 0.7%; and MPA: 4.4% and 2.2%,
respectively).
Higher levels of proteinuria were observed early after trans-
plantation and fell rapidly in the first month. Mean urinary
protein:creatinine ratios at Month 12 were comparable in
the everolimus 1.5 mg and MPA groups but higher in the
everolimus 3.0 mg group. Nephrotic proteinuria was rare
in all groups (Table 5). Severe proteinuria (assessed by
the investigator) was infrequent (0.7%, 1.4% and 0.4%
in the everolimus 1.5 mg, 3.0 mg and MPA groups, re-
spectively) (Table 4).
Adverse wound-healing events were reported in 35.0%,
38.8% and 25.6% of patients in the everolimus 1.5 mg,
3.0 mg and MPA groups, respectively; 10.6%, 12.6% and
6.6% required surgical intervention. A greater proportion
of wound-healing events were reported in patients in BMI
categories >50th percentile. In the everolimus groups,
wound-healing events were reported in 46–50% of pa-
tients with a BMI >75th percentile versus 27% of patients
in the MPA group (p < 0.05; Chi-squared test).
The only system-organ class for which severe AEs were
reported in >10% of patients was infections and infesta-
tions (5.8%, 10.1% and 7.3% in the everolimus 1.5 mg,
3.0 mg and MPA groups, respectively). Peripheral edema,
headache and hyperlipidemia were reported as severe AEs
by patients receiving everolimus but not MPA (peripheral
edema: 2.6% and 1.4%; headache: 1.1% and 0.4%; and
hyperlipidemia: 0.7% and 0.0%, in the everolimus 1.5 mg
and 3.0 mg groups, respectively). High total cholesterol and
triglyceride levels were more frequent in the everolimus
versus MPA groups (Table 5) and lipid-modifying agents
were prescribed to 64.6%, 72.3% and 57.5% of pa-
tients in the everolimus 1.5 mg, 3.0 mg and MPA groups,
respectively. Low lymphocyte counts were the most com-
monly reported hematologic parameter; high and low WBC
counts and low neutrophil counts were more frequently
observed in the MPA versus everolimus groups.
There were seven (2.6%), nine (3.2%) and six (2.2%)
deaths in the everolimus 1.5 mg, 3.0 mg and MPA groups,
respectively. The main causes were cardiac disorders (four
in each group), and infections and infestations (two, four
and one in the everolimus 1.5 mg, 3.0 mg and MPA groups,
respectively). Two deaths were suspected by the center
investigator to be related to the study drug: malignant
melanoma in the everolimus 1.5 mg group (the patient
had a history of melanoma prior to transplantation) and
chronic bronchopneumonia and congestive heart failure in
the everolimus 3.0 mg group.
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Table 4: Summary of adverse events over 12 months of treatment (safety population)
Everolimus 1.5 mg Everolimus 3.0 mg MPA 1.44 g
(N = 274) (N = 278) (N = 273)
Any AE 271 (98.9) 276 (99.3) 270 (98.9)
SAEs 155 (56.6) 168 (60.4) 147 (53.8)
Severe AEs 88 (32.1) 111 (39.9) 98 (35.9)
Any notable event1 165 (60.2) 183 (65.8) 155 (56.8)
AEs leading to study drug discontinuation2 64 (23.4) 79 (28.4) 43 (15.8)
AEs leading to study drug dose adjustment 61 (22.3) 75 (27.0) 95 (34.8)
Most frequently reported AEs and infections (≥20% of patients in any treatment group)3
Blood and lymphatic system disorders 93 (33.9) 112 (40.3) 111 (40.7)
Anemia 70 (25.5) 86 (30.9) 68 (24.9)
Gastrointestinal disorders 196 (71.5) 208 (74.8) 207 (75.8)
Constipation 105 (38.3) 122 (43.9) 117 (42.9)
Nausea 79 (28.8) 80 (28.8) 85 (31.1)
Vomiting 40 (14.6) 48 (17.3) 60 (22.0)
General disorders and administration site conditions 181 (66.1) 185 (66.5) 160 (58.6)
Peripheral edema 123 (44.9) 120 (43.2) 108 (39.6)
Infections and infestations 169 (61.7) 178 (64.0) 185 (67.8)
Urinary tract infection 60 (21.9) 57 (20.5) 63 (23.1)
Investigations 137 (50.0) 120 (43.2) 133 (48.7)
Increased blood creatinine 48 (17.5) 52 (18.7) 59 (21.6)
Metabolism and nutrition disorders 222 (81.0) 233 (83.8) 199 (72.9)
Hyperkalemia 49 (17.9) 58 (20.9) 48 (17.6)
Hyperlipidemia 57 (20.8) 60 (21.6) 43 (15.8)
Vascular disorders 122 (44.5) 137 (49.3) 124 (45.4)
Hypertension4 81 (29.6) 76 (27.3) 82 (30.0)
AEs commonly ascribed to CsA treatment
Tremor 23 (8.4) 22 (7.9) 38 (13.9)
Gingival hyperplasia 2 (0.7) 1 (0.4) 8 (2.9)
Gingival hypertrophy 3 (1.1) 2 (0.7) 6 (2.2)
Hirsutism 8 (2.9) 11 (4.0) 15 (5.5)
Renal and urinary disorders 112 (40.9) 143 (51.4) 124 (45.4)
AEs commonly associated with PSI/mTOR inhibitor treatment
Hyperlipidemia4 57 (20.8) 60 (21.6) 43 (15.8)
Proteinuria 25 (9.1) 36 (12.9) 20 (7.3)
Severity
Asymptomatic 1 (0.4) 1 (0.4) 0 (0.0)
Mild 15 (5.5) 18 (6.5) 14 (5.1)
Moderate 7 (2.6) 13 (4.7) 5 (1.8)
Severe 2 (0.7) 4 (1.4) 1 (0.4)
Mouth ulceration 9 (3.3) 14 (5.0) 5 (1.8)
Wound-healing event 96 (35.0) 108 (38.8) 70 (25.6)
Lymphocele 18 (6.6) 31 (11.2) 14 (5.1)
Impaired healing 5 (1.8) 11 (4.0) 3 (1.1)
Wound dehiscence 4 (1.5) 9 (3.2) 4 (1.5)
Data are n (%).
1Defined as death, nonfatal SAEs, AEs leading to discontinuation of study medication and adverse drop-out (drop-out due to AE, abnormal
laboratory values, or abnormal test procedure results); 2Patients with AEs leading to discontinuation of study medication may have had
another reason cited as their primary reason for discontinuation (see Figure 1); 3By primary system organ class and preferred term;
4Data are included in both categories. The AE database was searched for potential wound-healing events, and additional information
to determine the nature of these events was collected retrospectively, as outlined in the study protocol. This is the source for the
wound-healing data presented here.
AE = adverse event; MPA = mycophenolic acid; mTOR = mammalian target of rapamycin; PSI = proliferation-signal inhibitor; SAE =
serious adverse event.
Discussion
The A2309 study met its Month 12 primary endpoints:
both everolimus groups showed similar and statistically
noninferior outcomes to the MPA group with respect
to primary efficacy failure and renal function. Effi-
cacy and safety outcomes with everolimus treatment
were maintained with CsA minimization of ∼50% and
∼60% versus the MPA group by Months 6 and 12,
respectively.
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Table 5: Laboratory abnormalities over 12 months of treatment (safety population, on-treatment analysis)
Everolimus 1.5 mg Everolimus 3.0 mg MPA 1.44 g
(N = 274) (N = 278) (N = 273)
Hemoglobin <6 g/dL 4 (1.5) 1 (0.4) 0 (0.0)
White blood cells
<2.1 × 109/L 3 (1.1) 7 (2.5)1 10 (3.7)2
>15.9 × 109/L 69 (25.2) 67 (24.2)1 85 (31.3)2
Absolute neutrophils <1.1 × 109/L 5 (1.8) 10 (3.6) 17 (6.3)
Absolute lymphocytes <1.1 × 109/L 247 (90.1) 253 (91.3) 248 (91.2)
Eosinophils >11% 4 (1.5) 2 (0.7) 5 (1.8)
Platelets
<50 × 109/L 0 (0.0) 3 (1.1)1 1 (0.4)2
>699 × 109/L 3 (1.1) 1 (0.4)1 1 (0.4)2
Lipids
Cholesterol (total) >350 mg/dL 43 (15.7) 46 (16.5) 17 (6.3)2
Triglycerides >750 mg/dL 12 (4.4) 17 (6.1) 7 (2.6)2
High-density lipoprotein
≥193–270 mg/dL 68 (26.3)3 95 (36.7)3 81 (31.0)4
>270 mg/dL 20 (7.7)3 13 (5.0)3 17 (6.5)4
Lipid-modifying agents 177 (64.6) 201 (72.3) 157 (57.5)
Glucose
<2.5 mmol/L 25 (9.1) 16 (5.8) 31 (11.4)2
>13 mmol/L 39 (14.2) 42 (15.1) 46 (16.9)2
Urinary protein:creatinine ratio mg/g at Month 12
Mean (SD) 35.6 (66.3) 61.4 (165.2) 31.1 (68.7)
<30 (normal) 1 (0.5) 1 (0.6) 4 (2.0)
30–<300 (mild) 134 (71.3) 122 (68.5) 158 (77.1)
300–<3000 (subnephrotic) 46 (24.5) 44 (24.7) 26 (12.7)
≥3000 (nephrotic) 2 (1.1) 6 (3.4) 4 (2.0)
Data are mean n (%) unless otherwise stated.
Abnormality criteria were predefined.
1n = 277; 2n = 272; 3n = 259; 4n = 261.
MPA = mycophenolic acid.
Attempts to minimize CNI nephrotoxicity by reducing
or eliminating CNIs from immunosuppressive regimens
have often been limited by an increase in acute rejection
(19–21). Building upon previous data (8,12,13,22), this
study demonstrated that everolimus with RD-CsA was as
effective as MPA plus ST-CsA in preventing BPARs;
graft and patient survival rates were also comparable
between groups. Patients in the 3.0 mg everolimus group
(targeted to 6–12 ng/mL) had the lowest BPAR rates
while the time to BPAR as estimated by the K–M analysis
was similar between groups. The incidence of ≥Banff IIA
BPARs was numerically lower with the everolimus versus
MPA regimens. The incidence of AEs commonly associ-
ated with CNI exposure—tremor, hirsutism, gingival
hyperplasia and hypertrophy—were lower in the
everolimus groups. These differences are potentially
attributable to everolimus-facilitated CNI minimization.
Previous studies showed that compared with MPA,
patients receiving everolimus with ST-CsA display worse
renal function at the end of the first year (6,9). These
differences are due to a clinically recognized drug–drug
synergistic mechanism between PSIs/mTORs and CsA.
In the A2309 study, mean eGFR at Month 12 was sim-
ilar between groups (MDRD; LOCF analyses), although
the everolimus 1.5 mg regimen (targeted to 3–8 ng/mL)
was associated with numerically higher mean and median
eGFR versus the MPA regimen at Month 1, which per-
sisted over 12 months (on-treatment analyses). These data
were supported by sensitivity analyses including LOCF
for patients who died or experienced graft loss prior to
Month 12, and different methods of calculating renal func-
tion. As improvements in 12-month eGFR are associated
with improvements in long-term graft function (2–4,23),
these findings are clinically significant. In addition, catego-
rizing eGFR by NKF categories demonstrated that a greater
proportion of patients in the everolimus 1.5 mg group
(targeted to 3–8 ng/mL) achieved eGFR ≥60 mL/min/
1.73 m2 at Month 12 versus the 3.0 mg and MPA groups.
Also, a greater proportion of patients with eGFR in the
<30 or 30–60 mL/min/1.73 m2 NKF categories at Month 1
experienced improvement in their renal function to eGFR
≥60 mL/min/1.73 m2 by Month 12.
The overall safety profile of everolimus was similar to that
seen in previous studies (8,11–14); approximately 50 000
patient-years of everolimus experience now exists (24).
AEs associated with everolimus treatment appear to be
dose related, indicating that a trough level targeted to 3–
8 ng/mL has the optimal benefit:risk profile.
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A greater proportion of patients in the everolimus versus
MPA groups discontinued study drug due to an AE. These
differences were most likely due to the study’s open-label
design; investigators are likely to have a lower threshold
for discontinuing everolimus treatment due to unfamiliar-
ity with this drug. In addition, study-drug discontinuation
as a result of an AE is unlikely with MPA, as viable al-
ternatives are not available. In contrast, a lower number
of patients required dose reduction due to an AE in the
everolimus groups versus the MPA group and, in total,
the incidence of patients discontinuing plus those requir-
ing study-drug adjustment due to an AE was lower in
the everolimus 1.5 mg compared with the 3.0 mg and
MPA groups. A post hoc regression analysis demonstrated
that there was no significant relationship between the
everolimus trough level and the rate of discontinuation
(data not shown).
Certain AEs are more prevalent with mTOR inhibitors/PSIs,
namely hematologic disorders, wound-healing events,
hyperlipidemia and proteinuria. A higher incidence of
wound-healing events was observed with everolimus ver-
sus MPA treatment with the highest percentage in the
everolimus 3.0 mg (targeted to 6–12 ng/mL) group. The
incidence of impaired-healing events and wound dehis-
cence were similar between the MPA and everolimus
1.5 mg (targeted to 3–8 ng/mL) groups. Higher BMI
is a well-known factor associated with wound-healing
complications (25–27) and, as expected, patients with a
BMI >75th percentile in the everolimus groups had a
higher number of wound-healing events. In contrast, only
27% of wound-healing events occurred in the >75th per-
centile in the MPA group. A lower incidence of leukope-
nia was observed in the everolimus groups, while the
incidence of anemia and thrombocytopenia were simi-
lar in all groups. Total cholesterol values and the use
of lipid-modifying agents were higher in the everolimus
groups; these events were seldom reported as SAEs
and rarely led to study-drug discontinuation. In addition,
proteinuria was reported in a greater proportion of patients
in the everolimus 3.0 mg versus 1.5 mg and MPA groups;
severe proteinuria was infrequent in all groups.
A lower incidence of infections, particularly BK virus and
CMV were observed with everolimus versus MPA treat-
ment. The reduced incidence of CMV infections in the
present study is consistent with other clinical trials of
everolimus versus azathioprine and MMF in de novo
renal-transplant recipients (10,28). The incidence of CMV
syndrome and CMV disease was also lower in the
everolimus versus MPA groups. A lower incidence of
neoplasms was observed in the everolimus versus MPA
groups with the only case of melanoma (everolimus 1.5 mg
group; targeted to 3–8 ng/mL) being a recurrence of a pre-
transplantation event. These trends are consistent with the
antiproliferative effects of everolimus and its FDA approval
for advanced renal-cell carcinoma treatment after vascular
endothelial growth-factor-receptor inhibitor failure.
Several limitations should be considered when interpreting
these results. Some inaccuracy in AE reporting is perhaps
inevitable when assessed by individual investigators, with
AEs generally being underreported; however, investigators
may be more likely to report AEs in an open-label trial
including an unfamiliar drug, which may partially explain
the higher discontinuation rate ascribed to AEs in patients
in the everolimus versus MPA groups. Since the study
population was at low immunological-risk and a majority
of patients were Caucasian with low PRA levels, these
results may not be directly transferable to other trans-
plant populations. In addition, noninferiority studies deter-
mine that the study-drug-group response is noninferior to
the control but do not test for clinical differences. Lastly,
although the degree of proteinuria did not differ between
the everolimus 1.5 mg (targeted to 3–8 ng/mL) versus the
MPA groups, these results are based on 12-month data
and further follow-up is required.
In conclusion, the Month 12 outcomes from the A2309
study, the largest registration trial of everolimus in renal
transplantation to date, showed that everolimus targeted
to 3–8 ng/mL plus RD-CsA was as effective as MPA plus
ST-CsA with the best benefit-to-risk profile. CsA minimiza-
tion facilitated by everolimus treatment is a viable option
in the treatment of de novo renal-transplant recipients
that maintains efficacy and safety and has the potential to
offer long-term improvements in renal function. Results at
2 years will provide additional information on the long-term
safety of these regimens.
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